Precision Oncology at a Crossroads: How Organoid Platforms Are Reshaping the Field
Organoids · 29.05.2026 · 5 (2) · 16
DOI: 10.3390/organoids5020016 ↗Kurz gefasst
Fachartikel in der Zeitschrift Organoids, online erschienen am 29.05.2026. Verfasst von Seulbee Lee und 9 weiteren Autor:innen. Die Arbeit nennt 130 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Trade, Industry and Energy, National Research Foundation of Korea.
Abstract (Originalsprache)
Tumor heterogeneity and microenvironmental complexity remain fundamental barriers to genomics-centered precision oncology, frequently causing discordance between molecular alterations and real-world therapeutic responses. Here, we reviewed patient-derived organoid (PDO) technologies as functional platforms that complement molecular profiling by directly investigating patient-specific sensitivity, resistance, and microenvironment dependent vulnerability. We first summarize why conventional preclinical systems, two-dimensional cell lines and patient-derived xenografts, are limited by reduced biological fidelity, impractical turnaround time, and scalability for clinical decision support. We then synthesized organoid-based evidence across three representative disease malignancies with distinct precision-medicine bottlenecks. Across these settings, we highlight advances that extend the PDO capability beyond the tumor epithelium alone, including air–liquid interface cultures, immune and stromal co-cultures, and microfluidic organoid-on-chip systems, as well as integration with multi-omics and artificial intelligence for scalable analytics. Finally, we discuss the key translational requirements, standardization of culture matrices and assay readouts, quality control, automation to reduce turnaround time, and regulatory/ethical frameworks, required to transition organoid-guided testing from proof-of-concept to routine implementation. Collectively, this review reframes organoids as functional stratification platforms supporting the integration of functional response profiling alongside genomics-guided precision oncology approaches.
Förderung
- Ministry of Trade, Industry and Energy
- National Research Foundation of Korea
Zitieren
APA
Lee, S., Kim, A., Kim, R. H., You, S., Kim, H. S., Chung, S., Lee, S., Yahng, S., Kim, I. K., & Kim, H. J. (2026). Precision Oncology at a Crossroads: How Organoid Platforms Are Reshaping the Field. Organoids, 5(2), 16. https://doi.org/10.3390/organoids5020016
Vancouver
Lee S, Kim A, Kim RH, You S, Kim HS, Chung S, et al. Precision Oncology at a Crossroads: How Organoid Platforms Are Reshaping the Field. Organoids. 2026;5(2):16. doi:10.3390/organoids5020016
BibTeX
@article{Lee2026,
author = {Lee, Seulbee and Kim, Alyssa and Kim, Rachel Hyunkyung and You, Seo-Hee and Kim, Hyun Soo and Chung, Seok and Lee, Sang-Haak and Yahng, Seung-Ah and Kim, In Kyoung and Kim, Hye Joung},
title = {Precision Oncology at a Crossroads: How Organoid Platforms Are Reshaping the Field},
journal = {Organoids},
year = {2026},
volume = {5},
number = {2},
pages = {16},
doi = {10.3390/organoids5020016}
}
EUVIMED